Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder

Nitric oxide (NO) is a neurotransmitter that acts as a second messenger of the N‐methyl‐D‐aspartate receptor and interacts with the dopaminergic and the serotonergic systems. NO involvement in pathological processes relevant to neuropsychiatric disorders stems from its ability to modulate certain fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of medical genetics. Part B, Neuropsychiatric genetics Neuropsychiatric genetics, 2010-10, Vol.153B (7), p.1318-1328
Hauptverfasser: Silberberg, Gilad, Ben-Shachar, Dorit, Navon, Ruth
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nitric oxide (NO) is a neurotransmitter that acts as a second messenger of the N‐methyl‐D‐aspartate receptor and interacts with the dopaminergic and the serotonergic systems. NO involvement in pathological processes relevant to neuropsychiatric disorders stems from its ability to modulate certain forms of synaptic plasticity, and from its capacity to be transformed to a highly active free radical. Additionally, multiple links have been reported between the NO‐producing enzyme, nitric oxide synthase (NOS) 1, and both schizophrenia and bipolar disorder (BPD). RNA and DNA isolated from dorsolateral‐prefrontal cortices of schizophrenia patients, bipolar patients and controls (n = 26, 30 and 29, respectively) were donated by the Stanley Foundation Brain Collection. Gene expression was measured by Real‐Time‐PCR. Genetic polymorphisms were genotyped by restriction‐fragment length‐polymorphism analysis, and by product‐size determination of PCR products amplified with a fluorescent primer.Expression analysis of pan‐NOS1, as well as of 2 of its isoforms, “NOS1_1d” and “NOS1_1f”, which differ in their first exons and translational strength, revealed a trend for pan‐NOS1 over‐expression (P = 0.075) in schizophrenia patients (1.33‐fold), and significant over‐expression (P 
ISSN:1552-4841
1552-485X
1552-485X
DOI:10.1002/ajmg.b.31112